Table 12.2.
Recent funding amount breakdowns by type of threat for the Project BioShield program
Countermeasure area/product | Funding amount | Explanation |
---|---|---|
Anthrax | $1,456,130,000 | Antitoxins and vaccines |
Botulism | $476,000,000 | Antitoxins |
Smallpox | $1,085,000,000 | Vaccines |
Radionuclear | $234,500,000 | Radiation sickness |
Nerve agents | $60,800,000 | Midazolam for seizures |
From Department of Health and Human Services Project BioShield Annual Report: January–December 2013.